Skip to main content
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2002 Feb;78(916):92–93. doi: 10.1136/pmj.78.916.92

Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer

L Vini 1, S Hyer 1, A Al-Saadi 1, B Pratt 1, C Harmer 1
PMCID: PMC1742275  PMID: 11807191

Abstract

The aim of this study was to review the outcome of ablative radioiodine treatment on ovarian function in young women treated for differentiated thyroid carcinoma. Of 1398 patients with differentiated thyroid cancer, 496 were women under the age of 40 at the time of diagnosis who had received radioiodine therapy. Of these, 322 received a single 3 GBq ablation dose of radioiodine while the remainder received subsequent treatment with 131I with a cumulative activity of 8.5–59 GBq for residual, recurrent, or metastatic disease. Transient amenorrhoea or menstrual irregularities lasting up to 10 months were experienced in 83 patients (17%). No cases of permanent ovarian failure were recorded. There were 427 children born to 276 women; only one patient wishing to achieve a successful pregnancy outcome has been unsuccessful. Four premature births and 14 miscarriages occurred but no congenital abnormalities were reported. The risk of permanent damage to the ovaries after ablative radioiodine treatment appears to be low and patients can be reassured they can have normal pregnancies after this treatment.

Full Text

The Full Text of this article is available as a PDF (70.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dottorini M. E., Lomuscio G., Mazzucchelli L., Vignati A., Colombo L. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med. 1995 Jan;36(1):21–27. [PubMed] [Google Scholar]
  2. Harmer C. L., McCready V. R. Thyroid cancer: differentiated carcinoma. Cancer Treat Rev. 1996 May;22(3):161–177. doi: 10.1016/s0305-7372(96)90001-8. [DOI] [PubMed] [Google Scholar]
  3. Izembart M., Chavaudra J., Aubert B., Vallée G. Retrospective evaluation of the dose received by the ovary after radioactive iodine therapy for thyroid cancer. Eur J Nucl Med. 1992;19(4):243–247. doi: 10.1007/BF00175136. [DOI] [PubMed] [Google Scholar]
  4. Raymond J. P., Izembart M., Marliac V., Dagousset F., Merceron R. E., Vulpillat M., Vallée G. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J Clin Endocrinol Metab. 1989 Jul;69(1):186–190. doi: 10.1210/jcem-69-1-186. [DOI] [PubMed] [Google Scholar]
  5. Schlumberger M., De Vathaire F., Ceccarelli C., Delisle M. J., Francese C., Couette J. E., Pinchera A., Parmentier C. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med. 1996 Apr;37(4):606–612. [PubMed] [Google Scholar]
  6. Vini L., Harmer C. Radioiodine treatment for differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 2000;12(6):365–372. doi: 10.1053/clon.2000.9196. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES